Login
$TMO
$691.33 +$0.00 (0.0%) After hours

$TMO 8-K SEC Filings

Filed On Filing
30 Oct 2026 8-K: Departure/Election of Directors or Officers; Compensation

On October 27, 2026, Thermo Fisher Scientific Inc. (the “Company”), announced that Michael D. Shafer, Executive Vice President of the Company, will retire effective December 31, 2026.

21 Oct 2026 8-K: Results of Operations and Financial Condition

Outstanding performance driven by proven growth strategy and PPI Business System

23 Jul 2026 8-K: Results of Operations and Financial Condition

Customer Activity Across Our End Markets Continued to Strengthen

26 May 2026 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting held on May 20, 2026, the shareholders of the Company voted on the following proposals:

23 Apr 2026 8-K: Results of Operations and Financial Condition

WALTHAM, Mass. (April 23, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 28, 2026.

24 Mar 2026 8-K: Other Events

Thermo Fisher Scientific Completes Acquisition of Clario Holdings, Inc.

12 Feb 2026 8-K: Entry into a Material Definitive Agreement; Other Events

As Representatives of the several Underwriters named in Schedule A hereto

29 Jan 2026 8-K: Results of Operations and Financial Condition

WALTHAM, Mass. (January 29, 2026) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2025.

12 Jan 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

01 Dec 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As Lead Managers of the several Underwriters named in Schedule A hereto

29 Oct 2025 8-K: Other Events

Thermo Fisher Scientific to Acquire Clario Holdings, Inc., Enabling Pharma and Biotech Customers to Accelerate Innovation with Deeper Clinical Insights

22 Oct 2025 8-K: Results of Operations and Financial Condition

WALTHAM, Mass. (October 22, 2025) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the third quarter ended September 27, 2025.

07 Oct 2025 8-K: Entry into a Material Definitive Agreement; Other Events

As Representatives of the several Underwriters named in Schedule A hereto

02 Sep 2025 8-K: Other Events

Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets

23 Jul 2025 8-K: Departure/Election of Directors or Officers; Compensation

On July 23, 2025, Thermo Fisher Scientific Inc. (the “Company”), announced that Stephen Williamson, Senior Vice President and Chief Financial Officer (CFO) will retire effective March 31, 2026.

23 Jul 2025 8-K: Results of Operations and Financial Condition

WALTHAM, Mass. (July 23, 2025) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the second quarter ended June 28, 2025.

28 May 2025 8-K: Submission of Matters to a Vote of Security Holders

At the Annual Meeting held on May 21, 2025, the shareholders of the Company voted on the following proposals:

22 May 2025 8-K: Departure/Election of Directors or Officers; Compensation

This Performance-based Restricted Stock Unit Agreement (the “Agreement”) is made as of the Award Date set forth below between Thermo Fisher Scientific Inc., a Delaware corporation (the “Company”), and the Participant named below.

23 Apr 2025 8-K: Results of Operations and Financial Condition

WALTHAM, Mass. (April 23, 2025) – Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the first quarter ended March 29, 2025.

25 Feb 2025 8-K: Other Events

On February 25, 2025, Thermo Fisher Scientific Inc. (“Thermo Fisher”) and Solventum Corporation (“Solventum”) entered into an agreement, pursuant to which, subject to the satisfaction or waiver of specified conditions, Thermo Fisher agre...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support